AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-01 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
3 ArOH + FeCl3 → Fe(OAr)3 + 3 HCl (Ar = aryl) Among the halide and pseudohalide complexes, fluoro complexes of iron(III) are the most stable, with the colorless [FeF5(H2O)]2− being the most stable in aqueous solution. Chloro complexes are less stable and favor tetrahedral coordination as in FeCl4−; FeBr4− and FeI4− are reduced easily to iron(II). Thiocyanate is a common test for the presence of iron(III) as it forms the blood-red [FeSCN(H2O)5]2+. Like manganese(II), most iron(III) complexes are high-spin, the exceptions being those with ligands that are high in the spectrochemical series such as cyanide. An example of a low-spin iron(III) complex is [Fe(CN)6]3−. Iron shows a great variety of electronic spin states, including every possible spin quantum number value for a d-block element from 0 (diamagnetic) to 5⁄2 (5 unpaired electrons). This value is always half the number of unpaired electrons. Complexes with zero to two unpaired electrons are considered low-spin and those with four or five are considered high-spin. Iron(II) complexes are less stable than iron(III) complexes but the preference for O-donor ligands is less marked, so that for example [Fe(NH3)6]2+ is known while [Fe(NH3)6]3+ is not. They have a tendency to be oxidized to iron(III) but this can be moderated by low pH and the specific ligands used.
Cambridge selected cleaver blades for the first time in the history of the race, following the successful use of the oars in the 1992 Summer Olympics in Barcelona. The surface area of the cleaver was approximately 20% larger than the conventional macon blades. Oxford practised with cleaver blades in some of their outings leading up to the race, and were prepared to use them should the weather conditions be suitable, but on the day itself they opted to remain with the macon blades. The umpire for the race was the Canadian Olympic gold medallist and former Oxford Blue Mark Evans who had rowed in the 1983 and 1984 races. He caused controversy by instigating a new starting method whereby he would hold the crews for up to ten seconds between the conventional "set" and "go" commands. Evans had umpired the 1991 race in which he had also used his own starting method in preference to the traditional Amateur Rowing Association instructions. In response to any potential delay at the start during which time the boats will be dragged along with the tide, one of the stake-boat men, Bob Hastings, responsible for holding the boats until the "go" command is given stated: "If the boats start to drag I will let go, before I am dragged out of the stake-boat". Both Alan Inns, former coach and advisor to Cambridge, and Steve Royle, Oxford's director of rowing, expressed concerns over Evans' methodology.
== Expression of Draculin == As a naturally occurring anticoagulant, research into Draculin promises therapeutic strategy into new anticoagulants and provides a foundation for deeper investigations into FXa related coagulation mechanisms. Since the first step of the Draculin-FXa mechanism is driven by concentration and the second step is concentration independent, the FXa-Draculin complex behaves as irreversible under experimental conditions. Glycosylation is a common post-translational modification in which carbohydrates (glycans) are added to proteins or lipids. The resulting glycoproteins and glycolipids acquire altered physical and biochemical properties. As a glycoprotein, Draculin requires a specific glycosylation profile to express its maximum inhibitory activity. Its attached oligosaccharides are essential FXa inhibition, as demonstrated by the loss of anti-Xa activity following incubation with the lectins WGA and PNA.
Sources: en.wikipedia.org
The suspensory ligaments of Cooper play an important role in the change in appearance of the breast that often accompanies the development of inflammatory carcinoma of the breast in which blockage of the local lymphatic ducts causes swelling of the breast. Because the skin remains tethered by the suspensory ligaments of Cooper, it takes on a dimpled appearance reminiscent of the peel of an orange (peau d'orange). Carcinomas can also decrease the length of Cooper's ligaments leading to a dimpling.
Hayes, Sean (2022), "Burning Fat & Calories Post-Workout via the Afterburn Effect/EPOC." The Pliagility Blog. Lecheminant, J.; Jacobsen, D.; Bailey, B.; Mayo, M.; Hill, J.; Smith, B.; Donnelly, J. (2008). "Effects of Long-Term Aerobic Exercise on EPOC". International Journal of Sports Medicine. 29 (1): 53–8. doi:10.1055/s-2007-965111. PMID 17879880. Matsuo, Tomoaki; Ohkawara, Kazunori; Seino, Satoshi; Shimojo, Nobutake; Yamada, Shin; Ohshima, Hiroshi; Tanaka, Kiyoji; Mukai, Chiaki (2012). "Cardiorespiratory fitness level correlates inversely with excess post-exercise oxygen consumption after aerobic-type interval training". BMC Research Notes. 5: 646. doi:10.1186/1756-0500-5-646. PMC 3527216. PMID 23171610. Zeng, Ling-Qing; Zhang, Yao-Guang; Cao, Zhen-Dong; Fu, Shi-Jian (2010). "Effect of temperature on excess post-exercise oxygen consumption in juvenile southern catfish (Silurus meridionalis Chen) following exhaustive exercise". Fish Physiology and Biochemistry. 36 (4): 1243–52. doi:10.1007/s10695-010-9404-9. PMID 20499273. S2CID 24695117. Scott, Christopherb; Littlefield, Nathanaeld; Chason, Jeffreyd; Bunker, Michaelp; Asselin, Elizabethm (2006). "Differences in oxygen uptake but equivalent energy expenditure between a brief bout of cycling and running". Nutrition & Metabolism. 3: 1. doi:10.1186/1743-7075-3-1. PMC 1334197. PMID 16390548. Scott, Christopher (2005). "Misconceptions about Aerobic and Anaerobic Energy Expenditure". Journal of the International Society of Sports Nutrition. 2 (2): 32–7. doi:10.1186/1550-2783-2-2-32. PMC 2129144. PMID 18500953.
=== HIV === Drugs targeting PD-1 in combination with other negative immune checkpoint receptors, such as (TIGIT), may augment immune responses and/or facilitate HIV eradication. T lymphocytes exhibit elevated expression of PD-1 in cases of chronic HIV infection. Heightened presence of the PD-1 receptors corresponds to exhaustion of the HIV specific CD8+ cytotoxic and CD4+ helper T cell populations that are vital in combating the virus. Immune blockade of PD-1 resulted in restoration of T cell inflammatory phenotype necessary to combat the progression of disease.
Sources: en.wikipedia.org
In Piazza Castello converge some of the main streets of the city centre. Among them, one of the most significant is the arcaded Via Po, built by Amedeo di Castellamonte in 1674 and featuring some interesting buildings, such as the first and original building of the University of Turin and the historical Caffè Fiorio, which was the favourite café of the 19th-century politicians. Via Po ends in Piazza Vittorio Veneto (simply called Piazza Vittorio locally), the largest Baroque square in Europe and today heart of Turin nightlife. Piazza Vittorio features the most fashionable bars and not far from here, along the Po riverfront, the Murazzi quays used to host several bars and nightclubs open until the morning until a few years ago.
==== Leucine ==== The ammonia fixed as part of the glutamate dehydrogenase enzyme reaction in the neurons is transaminated into α-ketoisocaproate to form the branched-chain amino acid leucine, which is exported to the astrocytes, where the process is reversed. α-ketoisocaproate is transported in the other direction.
The influence of Nasser's Arab nationalism over the RCC was immediately apparent. The administration was instantly recognized by the neighbouring Arab nationalist regimes in Egypt, Syria, Iraq, and Sudan, with Egypt sending experts to aid the inexperienced RCC. Gaddafi propounded pan-Arab ideas, proclaiming the need for a single Arab state stretching across North Africa and the Middle East. In December 1969, Libya signed the Tripoli Charter alongside Egypt and Sudan. This established the Arab Revolutionary Front, a pan-national union designed as a first step towards the eventual political unification of the three nations. In 1970 Syria declared its intention to join. Nasser died unexpectedly in September 1970, with Gaddafi playing a prominent role at his funeral. Nasser was succeeded by Anwar Sadat, who replaced the idea of a unified state with a political federation, implemented in April 1971; in doing so, Egypt, Syria, and Sudan received large grants of Libyan oil money. In July 1971, Gaddafi sided with Sadat against the Soviet Union in the 1971 Sudanese coup d'état and dispatched Libyan fighter jets to force down a British Overseas Airways Corporation jetliner carrying the leading coup plotters, Farouk Osman Hamadallah and Babikir al-Nour. They were extradited back to Khartoum, where they were promptly executed by Sudanese leader Jaafar Nimeiry. In February 1972, Gaddafi and Sadat signed an unofficial charter of merger, but it was never implemented because relations broke down the next year.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.